{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.15","value":"-0.03"},{"groupId":"OG001","spread":"0.23","value":"-0.16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"156"}],"units":"Participants"}],"description":"The ASQoL score ranged from 0 to 18 with higher score indicating worse Health-Related Quality of Life (HRQoL) and 0 indicating good HRQoL. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.","dispersionType":"Standard Deviation","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Full Analysis Set (FAS).","id":"OG000","title":"Placebo (FAS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the FAS.","id":"OG001","title":"CZP 200 mg Q2W (FAS)"}],"paramType":"MEAN","populationDescription":"The FAS consisted of all subjects in the RS who have received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Baseline to Week 2","title":"Change From Baseline in ASQoL at Week 2","type":"SECONDARY","unitOfMeasure":"scores on a scale"}